substituted by 1 to 3 halogen atoms,
a biphenylyl group, or
a pyrazolyl group;
R is a hydrogen atom; or
A and R are optionally bonded to each other to form a dihydroisoindole ring having 1 or 2 oxo groups;
Q^1 is a hydrogen atom or a C_{1-6} alkyl group;
Q^2, Q^3 and Q^4 are each a hydrogen atom;
X is a hydrogen atom;
Y^1, Y^2 and Y^3 are each independently a hydrogen atom or a C_{3-8} cycloalkyl group;
Y^1 and Y^2 are optionally bonded to each other to form, together with the adjacent carbon atom,
a piperidine ring optionally having 1 to 3 C_{1-6} alkyl groups; and
Z^1, Z^2 and Z^3 are each a hydrogen atom,
or a salt thereof.

8. N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)biphenyl-4-carboxamide or a salt thereof.

9. N-(4-{trans-2-[(1-methylpiperidin-4-yl)amino]cyclopropyl}phenyl)-3-(trifluoromethyl)benzamide or a salt thereof.

10. N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-1H-pyrazole-4-carboxamide or a salt thereof.

11. A compound selected from
(1) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}-2-methylphenyl)benzamide,
(2) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-3-

(trifluoromethoxy)benzamide,
(3) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)benzamide,
(4) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-cyclohexanecarboxamide,
(5) N-(4-{trans-2-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino]cyclopropyl}phenyl)-3-(trifluoromethyl)benzamide,
(6) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide,
(7) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-1,5-dimethyl-1H-pyrazole-3-carboxamide,
(8) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide,
(9) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide, and
(10) N-(4-{trans-2-[(cyclopropylmethyl)amino]cyclopropyl}phenyl)-1-methyl-1H-pyrazole-4-carboxamide,
or a salt thereof.

12~~11~~. A medicament comprising the compound according to claim 1 or a salt thereof.

13~~12~~. The medicament according to claim 12~~11~~, which is a prophylactic or therapeutic agent for cancer.

14~~13~~. The medicament according to claim 12~~11~~, which is an LSD1 inhibitor.

15~~14~~. The medicament according to claim 12~~11~~, which is a

prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's chorea.

16~~15~~. A method for the prophylaxis or treatment of schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's chorea, comprising administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.

17~~16~~. Use of the compound according to claim 1 or a salt thereof for the production of a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's chorea.

18~~17~~. The compound according to claim 1 or a salt thereof for use in the prophylaxis or treatment of schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's chorea.

19~~18~~. A method of inhibiting LSD1, comprising administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.